Next Health, recognized as a leader in proactive healthcare, has announced a significant expansion into the Sacramento area, Walnut Creek, and Reno through an area development agreement. This move aligns…
OS Therapies (NYSE-A: OSTX), a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates, has announced the appointments of Avril McKean Dieser, MA, JD, and Olivier R. Jarry, MS,…
Henry Schein Medical, part of Henry Schein, Inc. (Nasdaq: HSIC), is exhibiting at the EMS & FIRE PRO Expo from October 24-26, 2024. Located at booth #718, the exhibit features…
Siemens Healthineers is revolutionizing clinical lab automation by consolidating 25 tasks typically performed manually by staff, significantly reducing manual workflow steps by 75%. Traditional lab automation relies on a track…
The CVS Health® Foundation has announced a $1.5 million funding initiative to enhance access to healthcare services, medically tailored meals, and transportation for chronic disease patients in Atlanta. This funding…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company using its proprietary ARCUS® platform for advanced in vivo gene editing therapies, announced a poster presentation at the European Society…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) has voted to update the pneumococcal vaccination guidelines…
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced positive topline interim results from their ongoing Phase 3 clinical trial of sibeprenlimab for treating immunoglobulin A…
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced its financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Financial Highlights Year-to-Date 2024 Financial Overview Balance Sheet and…
CurrentBody has successfully acquired Tria Beauty. In 2003, the inventors of LightSheer™, a leading in-clinic laser hair removal technology, aimed to revolutionize at-home hair removal by creating a handheld laser…
NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for…
Galderma has announced new Phase III data from the READY-4 clinical trial, showcasing the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess™) for treating frown lines and crow’s feet after repeated…